alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 176–200 of 739 studies published 2012 (page 8 of 30) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Brain : a journal of neurology 2012-03-01

The neuroimaging profile of the C9ORF72 expansion was significantly more symmetrical than progranulin mutations with significantly less temporal lobe involvement than microtubule-associated protein tau mutations. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers

✓ Peer-reviewed alzhub usefulness score 58 out of 100. PloS one 2012-03-22

Accurate prediction of clinical changes of mild cognitive impairment (MCI) patients, including both qualitative change (i.e., conversion to Alzheimer's disease (AD)) and quantitative change (i.e., cognitive scores) at future time points, is important for early diagnosis of AD and for monitoring the disease progression. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment in a community sample: the Sydney Memory and Ageing Study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2012-10-27

Incidence rates for MCI are higher than previously reported, particularly in men and for single-domain MCI; rates for amnestic and nonamnestic MCI were comparable. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Voxelwise meta-analysis of gray matter anomalies in Alzheimer's disease and mild cognitive impairment using anatomic likelihood estimation

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Journal of the neurological sciences 2012-03-03

Our meta-analysis identified similar distributions of neuroanatomical changes in AD and MCI, which are consistent with the hierarchical model of neuropathological alterations of neurofibrillary tangles in AD and MCI. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2012-01-18

Cerebral microbleeds are frequently found in the general elderly population and may reflect underlying vascular disease, but their role in cognitive function is unknown. 4 key findings →

Participants: 3,979 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Retinopathy and risk of dementia: the Rotterdam Study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2012-07-11

We investigated the associations between retinopathy and dementia and its subtypes Alzheimer disease (AD) and vascular dementia both cross-sectionally and prospectively in the Rotterdam Study, a large population-based cohort study. 4 key findings →

Design: cohort study Participants: 195 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2012-05-01

In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD. 3 key findings →

Design: cohort study Participants: 159 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Postoperative delirium: a 76-year-old woman with delirium following surgery

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA 2012-07-01

Delirium (acute confusion) complicates 15% to 50% of major operations in older adults and is associated with other major postoperative complications, prolonged length of stay, poor functional recovery, institutionalization, dementia, and death. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Lancet. Neurology 2012-11-06

These findings contribute to the understanding of preclinical familial Alzheimer's disease and help set the stage for assessment of amyloid-modifying treatments in the prevention of familial Alzheimer's disease. 1 key finding →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Rates of decline in Alzheimer disease decrease with age

✓ Peer-reviewed alzhub usefulness score 57 out of 100. PloS one 2012-08-02

Age is the strongest risk factor for sporadic Alzheimer disease (AD), yet the effects of age on rates of clinical decline and brain atrophy in AD have been largely unexplored. 2 key findings →

Design: longitudinal study Participants: 723 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Caregiving burden, stress, and health effects among family caregivers of adult cancer patients

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA 2012-01-01

Unlike professional caregivers such as physicians and nurses, informal caregivers, typically family members or friends, provide care to individuals with a variety of conditions including advanced age, dementia, and cancer. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The impact of family caregivers on potentially inappropriate medication use in noninstitutionalized older adults with dementia

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of geriatric pharmacotherapy 2012-06-09

PIM use may be higher in dementia patients and their informal caregivers compared with the general older adult population. 5 key findings →

Participants: 566 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD 2012-01-01

Identification of potentially modifiable risk factors for cognitive deterioration is important. 5 key findings →

Participants: 5,607 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Engagement in social activities and progression from mild to severe cognitive impairment: the MYHAT study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. International psychogeriatrics 2012-12-21

Alternatively, lesser engagement in social activities may be a marker of impending cognitive decline in MCI. 1 key finding →

Design: cohort study Participants: 78 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The effects of cognitive speed of processing training among older adults with psychometrically- defined mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Current Alzheimer research 2012-11-01

Despite the growing interest in cognitive training programs as a potential non-pharmacological approach to slowing cognitive decline in mild cognitive impairment (MCI), there has been little research on the differential effectiveness of training among subtypes of MCI (i.e., amnestic, single non-amnestic, and multi-domain). 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Amygdala and hippocampal volume reductions as candidate endophenotypes for borderline personality disorder: a meta-analysis of magnetic resonance imaging studies

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Psychiatry research 2012-03-01

Borderline personality disorder (BPD) is a genetically influenced psychiatric illness with disruptions in neural systems supporting cognition and emotion regulation. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy 2012-10-29

Mean age of completers (n = 30) was 73.5 years and mean Mini-Mental Status Examination (MMSE) score was 22.5. 3 key findings →

Design: open-label trial Participants: 30 Evidence: high

Full summary, score breakdown and related studies → Original source

Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurobiology of aging 2012-04-13

In order to assess the frequency of mutations in the known Alzheimer's disease causative genes in Turkish dementia patients we screened amyloid precursor protein (APP), PSEN1 and PSEN2 for mutations in a cohort of 98 Turkish dementia families. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Nutritional treatment of aged individuals with Alzheimer disease living at home with their spouses: study protocol for a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Trials 2012-05-24

This study provides data on whether tailored nutritional care is beneficial to home-dwelling AD patients and their spouses. 5 key findings →

Participants: 202 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed